NCT04125290View on ClinicalTrials.gov

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

TerminatedOBSERVATIONAL

Enrollment

2

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

June 21, 2021

Study Completion Date

June 21, 2021

Conditions

Hairy Cell Leukemia

Trial Locations (2)

63044

Research Site, Bridgeton

81008

Rocky Mountain Cancer Centers, Pueblo

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Iqvia Pty Ltd

INDUSTRY

lead

AstraZeneca

INDUSTRY